ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Resverlogix Corp

Resverlogix Corp (RVX)

0,055
0,00
(0,00%)
Geschlossen 26 Dezember 10:12PM

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
0,055
Gebot
0,05
Fragen
0,055
Volumen
248.000
0,05 Tagesbereich 0,055
0,04 52-Wochen-Bereich 0,095
Marktkapitalisierung
Handelsende
0,055
Handelsbeginn
0,055
Letzte Trade
1000
@
0.055
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
63.538
Ausgegebene Aktien
272.371.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,81
Gewinn pro Aktie (EPS)
-0,06
Erlöse
57k
Nettogewinn
-16,74M

Über Resverlogix Corp

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Hauptsitz
Calgary, Alberta, Can
Gegründet
-
Resverlogix Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Börse with ticker RVX. The last closing price for Resverlogix was $0,06. Over the last year, Resverlogix shares have traded in a share price range of $ 0,04 to $ 0,095.

Resverlogix currently has 272.371.000 shares in issue. The market capitalisation of Resverlogix is $14,98 million. Resverlogix has a price to earnings ratio (PE ratio) of -0.81.

RVX Neueste Nachrichten

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global leader in the development of epigenetic therapeutics, today announced that Donald...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1000.0550.060.05813880.055CS
4-0.005-8.333333333330.060.060.05882840.05681243CS
120.005100.050.070.05635380.05940941CS
260.005100.050.0950.04796550.0669737CS
52-0.015-21.42857142860.070.0950.04575160.06547205CS
156-0.515-90.3508771930.570.820.04676490.17469086CS
260-1.145-95.41666666671.21.530.04645800.43922439CS

RVX - Frequently Asked Questions (FAQ)

What is the current Resverlogix share price?
The current share price of Resverlogix is $ 0,055
How many Resverlogix shares are in issue?
Resverlogix has 272.371.000 shares in issue
What is the market cap of Resverlogix?
The market capitalisation of Resverlogix is CAD 14,98M
What is the 1 year trading range for Resverlogix share price?
Resverlogix has traded in the range of $ 0,04 to $ 0,095 during the past year
What is the PE ratio of Resverlogix?
The price to earnings ratio of Resverlogix is -0,81
What is the cash to sales ratio of Resverlogix?
The cash to sales ratio of Resverlogix is 250
What is the reporting currency for Resverlogix?
Resverlogix reports financial results in USD
What is the latest annual turnover for Resverlogix?
The latest annual turnover of Resverlogix is USD 57k
What is the latest annual profit for Resverlogix?
The latest annual profit of Resverlogix is USD -16,74M
What is the registered address of Resverlogix?
The registered address for Resverlogix is 4820 RICHARD ROAD S.W, SUITE 300, CALGARY, ALBERTA, T3E 6L1
What is the Resverlogix website address?
The website address for Resverlogix is www.resverlogix.com
Which industry sector does Resverlogix operate in?
Resverlogix operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
GMTNGold Mountain Mining Corp
$ 0,035
(16,67%)
10k
XLYAuxly Cannabis Group Inc
$ 0,035
(16,67%)
378,93k
PPRPrairie Provident Resources Inc
$ 0,035
(16,67%)
390k
WRXWestern Resources Corp
$ 0,04
(14,29%)
3k
GFRGreenfire Resources Ltd
$ 10,09
(13,37%)
31,9k
RTGRTG Mining Inc
$ 0,025
(-37,50%)
100k
NCFNorthcliff Resources Ltd
$ 0,02
(-20,00%)
1,03M
KLSKelso Technologies Inc
$ 0,11
(-15,38%)
3,5k
AVLAvalon Advanced Materials Inc
$ 0,035
(-12,50%)
114k
YRBYorbeau Resources Inc
$ 0,035
(-12,50%)
110k
TTelus Corp
$ 19,45
(-1,52%)
4,87M
BBBlackBerry Limited
$ 5,65
(4,05%)
3,61M
ABXBarrick Gold Corporation
$ 22,55
(0,71%)
3,57M
BITFBitfarms Ltd
$ 2,45
(6,06%)
3,26M
FCUFission Uranium Corp
$ 0,72
(-2,70%)
2,54M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock